Q3 2026 Teleflex Incorporated Earnings Call Presentation

Third Quarter 2026 Earnings Conference Call

11/5/2026

The release, accompanying slides, and replay webcast are available online at https://www.teleflex.com (click on Investors)

An audio replay of the call will be available beginning at 11:00 am Eastern Time on November 5, 2026 either on the Teleflex website or by telephone.

The call can be accessed by dialing

1 833 309 1852 (U.S. and Canada) or 1 929 828

5978

(all other locations).

The confirmation code is 893 259 060.

President and CEO

Executive VP and CFO

TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

This presentation contains forward-looking statements, including, but not limited to, our forecasted 2026: GAAP, pro forma adjusted revenue and pro forma adjusted constant currency revenue growth, GAAP and adjusted operating margin and GAAP and adjusted earnings per share and, in each case, our estimates with respect to the items expected to impact those forecasted results; statements regarding our planned uses of the net proceeds from the closing of the sale of our OEM business (the "OEM Strategic Divestiture"), including, without limitation, with respect to the paydown of debt and the repurchase of shares of our outstanding common stock; statements regarding our expectations with respect to the timing for closing of the sales of our Acute Care and Interventional Urology businesses (which, together with the OEM Strategic Divestiture, we refer to as the "Strategic Divestitures"); statements regarding projected costs, savings and timing with respect to restructuring activities related to the Strategic Divestitures; our expectation that the transition services and manufacturing services agreements to be entered into in connection with the Strategic Divestitures will offset stranded costs on an annualized basis; statements regarding EZPLAZ; statements regarding our BIOMAG-II and BIOMAG-III trials and our BIOMAG-LL clinical study; our expectation that our financial profile will be meaningfully stronger starting in 2027; and other matters which inherently involve risks and uncertainties which could cause actual results to differ from those projected or implied in the forward-looking statements. Any forward-looking statements contained herein are based on our management's current beliefs and expectations, but are subject to a number of risks, uncertainties and changes in circumstances, which may cause actual results or company actions to differ materially from what is expressed or implied by these statements. These risks and uncertainties are identified and described in more detail in our filings with the Securities and Exchange Commission, including our Annual Report on Form 10-K. We expressly disclaim any obligation to update these forward-looking statements, except as otherwise explicitly stated by us or as required by law or regulation. You should not place undue reliance on these statements or the scientific data presented.

This presentation refers to certain non-GAAP financial measures, including, but not limited to, pro forma adjusted revenue, pro forma adjusted constant currency revenue growth, adjusted diluted earnings per share, adjusted gross and operating margins, adjusted selling, general and administrative expenses, adjusted research and development expenses, adjusted income before taxes, adjusted income tax expense and adjusted tax rate. These non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures. Tables reconciling these non-GAAP financial measures to the most comparable GAAP financial measures are contained within this presentation and the appendices at the end of this presentation.

This document contains certain highlights with respect to our third quarter 2026 results and developments and does not purport to be a complete summary thereof. Accordingly, we encourage you to read our Earnings Release for the quarter ended September 30, 2026 located in the investor section of our website at https://www.teleflex.com and our Quarterly Report on Form 10-Q for the quarter ended September 30, 2026 to be filed with the Securities and Exchange Commission.

Unless otherwise noted, the following slides reflect continuing operations.

4 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

Jason Weidman President and CEO

• Q3'26 pro forma adjusted constant currency revenue grew 3.0%

  year-over-year

• Q3'26 adjusted gross margin of 66.8% and adjusted operating margin of 25.0%

• Q3'26 adjusted EPS of $2.63, a 39.2% increase year-over-year

OEM Divestiture Update

• Closed the OEM Strategic Divestiture for $1.5 billion in proceeds ($1.25 billion after-tax)

• OEM Strategic Divestiture generates the majority of our expected

and

proceeds from the Strategic Divestitures - funded debt paydown

share repurchase

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

EZPLAZTM: Building a Long-Term Growth Driver

• First and only FDA-licensed freeze dried plasma; approved in late July; customer interest has been high

• Stored at room temperature and ready to reconstitute in minutes - makes plasma available on the battlefield, in air and road ambulances, and in trauma centers without waiting to thaw1,2

• Flexible bag is a meaningful differentiator vs. glass-container formats expected from future entrants; first-mover advantage positions EZPLAZ to set the standard

• Initial priority is the U.S. government and military, expected to account for the majority of current manufacturing capacity; Department of War discussions continue to progress

EXPECTED REVENUE PROFILE

1. Pusateri AE, Given MB, Schreiber MA, et al. Dried plasma: state of the science and recent developments. Transfusion. 2016;56 Suppl 2:S128-S139. doi:10.1111/ trf.13580

2. Hervig T, Doughty H, Ness P, et al. Prehospital use of plasma: the blood bankers' perspective. Shock. 2014;41 Suppl 1:39-43. doi:10.1097/SHK.0000000000000144

Rx Only

See appendices to this presentation for EZPLAZ™ Freeze Dried Plasma Indications and Important Safety Information.

7 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

FreesolveTM Resorbable Magnesium Scaffold (RMS) Breakthrough Device Designation Received

• Received FDA Breakthrough Device Designation (BDD) for FreesolveTM RMS in percutaneous coronary intervention (PCI), building on the 2024 BDD for below-the-knee (BTK) treatment of chronic limb-ischemia

• BIOMAGTM-II: enrollment completed ahead of schedule; one-year data vs. XIENCETM Drug-Eluting Stent (DES) expected in late 2027

• BIOMAGTM-III: U.S. pivotal trial underway to support a future Premarket Approval (PMA) submission

  BIOMAGTM-LL Clinical Study Enrollment Completed

• Completed enrollment of 102 patients across 14 European centers evaluating 35 mm and 40 mm FreesolveTM RMS lengths in de novo coronary lesions up to 38 mm

• Primary endpoint is 12-month target lesion failure (TLF)*

• Study will help determine whether longer scaffold lengths may enable treatment of long lesions with fewer implants, potentially simplifying procedures and reducing scaffold overlap

• 35 mm and 40 mm lengths are also included in the ongoing BIOMAGTM-III pivotal clinical trial

*Target lesion failure (TLF) is a composite clinical endpoint commonly used to assess the safety and effectiveness of coronary interventional devices.

CAUTION-Investigational device. Limited by the United States law to investigational use.

FreesolveTM RMS is not for sale in the United States and is commercially available in CE-mark accepting countries only. Indications for Use may vary by geographic location.

8 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

Sales ($M) Commentary

$243.5

Reported rev. growth: 4.7% Pro forma adj. const. curr. rev. growth: 4.6%

• In Q3'26, growth was primarily driven by our intraosseous portfolio, hemostatic products, and peripheral access products

• As expected, saw some distributor inventory destocking associated with normalization following the lidocaine recall earlier in the year

  Interventional

$210.3

Reported rev. growth: (2.6)% Pro forma adj. const. curr. rev. growth: 0.2%

$114.0

Reported rev. growth: 4.2% Pro forma adj. const. curr. rev. growth: 5.1%

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. Pro forma adjusted constant currency revenue growth is as compared to the prior year period.

9 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

Three Months Ended September 30, 2026

Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

1. Adjustments are inclusive of Vascular Intervention pro forma and discontinued product adjustments

2. Adjustments are inclusive of discontinued product adjustments

3. In 2025, amounts reflect the impact from decreases in our reserves related to the Italian payback measure pertaining to prior years.

10 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

John Deren

Executive VP and CFO

Adjusted GAAP

2025 62.3%

450

bps

2026 66.8%

2025 32.7%

2026 34.3%

2025 7.6%

2026 7.5%

2025 22.0%

300

bps

2026 25.0%

2025 $1.89

2026 $2.63

2025 51.5%

2026 65.0%

2025 36.6%

2026 38.9%

2025 7.8%

2026 7.6%

• The year-over-year adjusted gross margin increase was primarily driven by the following:

  • a 290 bps benefit from a refund related to 2026 IEEPA tariff payments

  • and foreign currency fluctuations, partially offset by an increase in quality remediation charges

    SG&A Expense

    (% of Sales)

• The year-over-year adjusted SG&A expense % of sales increase was driven by the following:

  • operating expenses associated with business and employee investments

    R&D Expense

    (% of Sales)

• Year-over-year adjusted R&D expense % of sales was flat

  Operating Margin

2025 (11.0)%

2026 18.6%

• The year-over-year adjusted operating margin increase was driven by the following:

  • year-over-year gross margin increase

    Earnings per Share

Note: See appendices for reconciliations of non-GAAP financial information.

12 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

2025

$1.30

2026

• The year-over-year adjusted earnings per share increase was driven by the following:

  • higher sales volume, lower interest expense and shares outstanding, and tariff refunds

    Capital Allocation Strategy Update

    Capital return commitment

    • $1 billion share repurchase authorization and $800 million reduction in debt

    • Near-term capital return to shareholders to be primarily funded by after-tax proceeds from the Strategic Divestitures

      Share repurchases

    • From July 1, 2026 through the date of this presentation, the Company has repurchased $350 million of its common stock through an ASR program ($250 million) and open market purchases ($100 million)

    • This consisted of 2.7 million shares repurchased at an average price of $128.96 per share

    • As of November 5, 2026, the Company had $400 million remaining available under the current authorization

TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026 13

• Maintaining 2026 pro forma adjusted constant currency revenue growth range of 3.5% to 4.5% year-over-year

• Reducing 2026 GAAP revenue from continuing operations growth range to 13.2% to 14.2% year-over-year due to changes in foreign currency exchange rates

  Earnings Per Share

  • Increasing 2026 Adjusted diluted EPS from continuing operations range to $7.50 to $7.75

  • Increasing 2026 GAAP EPS from continuing operations range to $2.84 to $3.09

  Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information. TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026 14

  2026 Guidance Considerations

  • 3.5% to 4.5% pro forma adjusted constant currency revenue growth for 2026

    Pro Forma Adj. CC Revenue Growth

• Excludes foreign exchange, Italian payback measure, and discontinued products

• Includes Vascular Intervention revenue for the first half of 2025

  Adjusted Earnings Per Share

• 2026 adjusted EPS from continuing operations in the range of $7.50 to $7.75

• Assumes:

  • ~20.0% adjusted operating margin inclusive of IEEPA tariff refunds of $16.5M recognized in the third quarter 2026

  • ~11.5% adjusted tax rate

  • $85M of net interest expense

  • 42.5 million shares outstanding for 2026

  • Reflects execution of capital allocation strategy, including pay off of $700 million Term Loan A-2, pay down of a portion of the revolving credit facility, and $600 million of share repurchases

  • Excludes transition services (TS) and manufacturing services (MS) benefits from the Acute Care & Interventional Urology Strategic Divestiture

  • Excludes future repurchases under the $1B buyback program funded by Strategic Divestitures proceeds, of which $400 million is remaining

  • Excludes incremental debt paydown with net proceeds from the Strategic Divestitures

    Note: See tables appearing in this presentation and the appendices hereto for reconciliations of non-GAAP financial information.

    TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026 15

    2026 Financial Guidance - Future Opportunities

    Adjusted Operating Margin

• TS/MS agreements expected to offset stranded costs on an annualized basis following close of AC/IU Strategic Divestiture

• Previously announced restructuring programs to result in ~$50 million of pre-tax savings on an annualized basis upon completion in mid-2028, which will contribute to mitigating stranded costs

  Debt Paydown

  • Intent to pay down ~$800M in debt (paid off $700 million of debt associated with the Vascular Intervention acquisition), with net proceeds from the Strategic Divestitures

  Share Repurchase

  • Remaining $400 million authorization under previously announced share repurchase program to be funded with net proceeds from the Strategic Divestitures

• Working on additional cost savings to further mitigate stranded costs

TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026 16

Note: See appendices for reconciliations of non-GAAP financial information.

17 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

Note: See appendices for reconciliations of non-GAAP financial information.

18 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

Strong Q3 Performance; Raising FY26 Adjusted EPS Guidance

• Expanded adj. margins; grew adj. EPS

• Vascular & Surgical solid; Interventional moving in the right direction

• Maintaining FY26 revenue growth outlook

Meaningful Progress on Our Transformation

• Interventional integration advancing with new leadership in place

• Confident in completing the AC/IU divestiture

• Advancing longer-term growth with EZPLAZ and Freesolve

Clear Path to a Meaningful Step-Up in 2027+

• Priorities: strengthen foundation, accelerate organizational effectiveness, elevate growth profile

• Planned completion of $1B buyback after AC/IU close

• 2027 step-up in adj. op. margin & EPS; sustainable growth beyond

19 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026

Thank You!

20 TELEFLEX EARNINGS CONFERENCE CALL 11/5/2026